Skip to main content
Premium Trial:

Request an Annual Quote

Siga Technologies Awarded $3.2M for Computational Design of Antiviral Agents for US Air Force

NEW YORK, Sept. 28 (GenomeWeb News) - Siga Technologies said yesterday that it has been awarded a one-year contract worth $3.2 million from the US Army Medical Research and Materiel Command to computationally design drugs to inhibit pathogens that are considered biowarfare threats.


The award, funded through the US Air Force, will support the design of antiviral compounds against smallpox and adenovirus.


Smallpox is a "Category A" biothreat agent under the Centers for Disease Control and Prevention's classification system, and adenovirus can cause respiratory infectious disease. Both pathogens "may impair the combat readiness of USAF personnel," the company said in a statement.


Bernard Kasten, the company's CEO, told GenomeWeb News that the firm will use molecular modeling software from Molsoft to computationally screen compound libraries against protein targets that have been identified in the pathogens.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.